Stanley T. Crooke Sells 11,000 Shares of Ionis Pharmaceuticals Inc. (IONS) Stock
Ionis Pharmaceuticals Inc. (NASDAQ:IONS) Chairman Stanley T. Crooke sold 11,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 5th. The shares were sold at an average price of $36.61, for a total value of $402,710.00. Following the completion of the transaction, the chairman now directly owns 35,029 shares of the company’s stock, valued at $1,282,411.69. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Shares of Ionis Pharmaceuticals Inc. (NASDAQ:IONS) opened at 34.26 on Friday. Ionis Pharmaceuticals Inc. has a one year low of $19.59 and a one year high of $65.34. The firm has a 50-day moving average price of $32.65 and a 200 day moving average price of $32.31. The stock’s market capitalization is $4.14 billion.
Ionis Pharmaceuticals (NASDAQ:IONS) last posted its quarterly earnings results on Tuesday, August 9th. The company reported ($0.47) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.52) by $0.05. Ionis Pharmaceuticals had a negative return on equity of 126.88% and a negative net margin of 128.94%. The firm had revenue of $38.50 million for the quarter, compared to the consensus estimate of $38.52 million. Ionis Pharmaceuticals’s revenue for the quarter was down 68.0% on a year-over-year basis. On average, equities analysts expect that Ionis Pharmaceuticals Inc. will post ($1.11) EPS for the current fiscal year.
Hedge funds have recently bought and sold shares of the stock. Parametric Risk Advisors LLC acquired a new stake in Ionis Pharmaceuticals during the first quarter worth $106,000. Rockefeller Financial Services Inc. acquired a new stake in Ionis Pharmaceuticals during the second quarter worth $114,000. Opera Trading Capital increased its stake in Ionis Pharmaceuticals by 150.0% in the first quarter. Opera Trading Capital now owns 2,892 shares of the company’s stock worth $117,000 after buying an additional 1,735 shares during the period. US Bancorp DE increased its stake in Ionis Pharmaceuticals by 37.8% in the second quarter. US Bancorp DE now owns 5,952 shares of the company’s stock worth $139,000 after buying an additional 1,634 shares during the period. Finally, GAM Holding AG increased its stake in Ionis Pharmaceuticals by 118.5% in the second quarter. GAM Holding AG now owns 7,727 shares of the company’s stock worth $180,000 after buying an additional 4,191 shares during the period. Hedge funds and other institutional investors own 89.58% of the company’s stock.
Several research analysts have recently weighed in on IONS shares. Piper Jaffray Cos. reaffirmed a “buy” rating and set a $35.00 target price on shares of Ionis Pharmaceuticals in a research note on Friday, June 10th. Zacks Investment Research downgraded Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, July 6th. BMO Capital Markets reaffirmed a “market perform” rating and set a $26.00 target price on shares of Ionis Pharmaceuticals in a research note on Friday, July 8th. Needham & Company LLC reaffirmed a “buy” rating and set a $55.00 target price on shares of Ionis Pharmaceuticals in a research note on Friday, July 8th. Finally, Cowen and Company reaffirmed a “hold” rating on shares of Ionis Pharmaceuticals in a research note on Thursday, July 14th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Ionis Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $42.92.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc, formerly Isis Pharmaceuticals, Inc, is engaged in discovering and developing ribonucleic acid-targeted (RNA-targeted) therapeutics. The Company operates through two segments: Ionis Core and Akcea Therapeutics. The Company’s Ionis Core segment is developing a drug discovery platform.
Receive News & Stock Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.